Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $89.9 million.

  • Axsome Therapeutics' Other Non-Current Liabilities rose 830.32% to $89.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year increase of 830.32%. This contributed to the annual value of $91.7 million for FY2024, which is 2507.5% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Other Non-Current Liabilities stood at $89.9 million, which was up 830.32% from $79.7 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Other Non-Current Liabilities peaked at $91.7 million during Q4 2024, and registered a low of $27.4 million during Q3 2022.
  • Its 4-year average for Other Non-Current Liabilities is $59.3 million, with a median of $69.8 million in 2024.
  • Per our database at Business Quant, Axsome Therapeutics' Other Non-Current Liabilities skyrocketed by 16301.11% in 2024 and then soared by 830.32% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Other Non-Current Liabilities (Quarter) stood at $31.1 million in 2022, then surged by 135.69% to $73.3 million in 2023, then increased by 25.08% to $91.7 million in 2024, then decreased by 1.97% to $89.9 million in 2025.
  • Its Other Non-Current Liabilities was $89.9 million in Q3 2025, compared to $79.7 million in Q2 2025 and $90.6 million in Q1 2025.